Foghorn Therapeutics, Inc. files for IPO.

IPO of Foghorn Therapeutics, Inc. (FHTX) will take place on October 22, 2020. Foghorn Therapeutics are pioneers in the discovery and development of a new class of medicines targeting diseases with genetically determined dependencies in the chromatin regulatory system, which is an untapped opportunity for therapeutic intervention. Foghorn Therapeutics' proprietary gene traffic management platform provides a comprehensive, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing the identification, validation and use of medical targets in the system. 
The estimated value of the company after its IPO will be $545 million.
Goldman Sachs, Morgan Stanley, Cowen and Wedbush PacGrow are listed bookrunners of the deal.